David C Huang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3880605/publications.pdf

Version: 2024-02-01

234 papers	38,707 citations	3159 92 h-index	2747 192 g-index
241 all docs	241 docs citations	241 times ranked	33202 citing authors

#	Article	IF	Citations
1	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 2013, 19, 202-208.	30.7	2,426
2	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular Cell, 2005, 17, 393-403.	9.7	1,639
3	Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. Science, 1999, 286, 1735-1738.	12.6	1,386
4	The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene, 2003, 22, 8590-8607.	5.9	1,342
5	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-399.	16.8	1,149
6	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes and Development, 2005, 19, 1294-1305.	5.9	1,071
7	Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak. Science, 2007, 315, 856-859.	12.6	1,021
8	Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO Journal, 1998, 17, 384-395.	7.8	1,005
9	The Proapoptotic Activity of the Bcl-2 Family Member Bim Is Regulated by Interaction with the Dynein Motor Complex. Molecular Cell, 1999, 3, 287-296.	9.7	964
10	BH3-Only Proteinsâ€"Essential Initiators of Apoptotic Cell Death. Cell, 2000, 103, 839-842.	28.9	964
11	Programmed Anuclear Cell Death Delimits Platelet Life Span. Cell, 2007, 128, 1173-1186.	28.9	910
12	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	27.8	830
13	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology, 2012, 30, 488-496.	1.6	719
14	Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production. Cell, 2014, 159, 1549-1562.	28.9	698
15	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 2011, 471, 110-114.	27.8	682
16	Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis.. EMBO Journal, 1995, 14, 6136-6147.	7.8	643
17	Bmf: A Proapoptotic BH3-Only Protein Regulated by Interaction with the Myosin V Actin Motor Complex, Activated by Anoikis. Science, 2001, 293, 1829-1832.	12.6	555
18	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010, 463, 103-107.	27.8	529

#	Article	IF	Citations
19	Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature, 2002, 419, 634-637.	27.8	517
20	Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis. Cell, 2013, 152, 519-531.	28.9	491
21	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science Translational Medicine, 2015, 7, 279ra40.	12.4	430
22	XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 2009, 460, 1035-1039.	27.8	421
23	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135, 791-803.	1.4	412
24	Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6217-6222.	7.1	397
25	Structure-guided design of a selective BCL-XL inhibitor. Nature Chemical Biology, 2013, 9, 390-397.	8.0	324
26	The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.. EMBO Journal, 1996, 15, 6979-6990.	7.8	319
27	A Cluster of Interferon-Î³-Inducible p65 GTPases Plays a Critical Role in Host Defense against Toxoplasma gondii. Immunity, 2012, 37, 302-313.	14.3	311
28	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14907-14912.	7.1	310
29	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discovery, 2018, 8, 1582-1597.	9.4	310
30	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery, 2019, 9, 342-353.	9.4	306
31	How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Research, 2006, 16, 203-213.	12.0	301
32	Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics. PLoS Medicine, 2007, 4, e316.	8.4	297
33	Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14871-14876.	7.1	296
34	The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO Journal, 1997, 16, 4628-4638.	7.8	290
35	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood, 2009, 114, 663-666.	1.4	274
36	The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments. Immunity, 2012, 36, 646-657.	14.3	272

#	Article	IF	Citations
37	Bcl-xLâ€“inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood, 2011, 118, 1663-1674.	1.4	262
38	Induction of cell death by tumour necrosis factor (TNF) receptor 2,CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO Journal, 1999, 18, 3034-3043.	7.8	255
39	Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO Journal, 1995, 14, 6136-47.	7.8	245
40	Bcl-2, Bcl-xL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene, 1997, 14, 405-414.	5.9	244
41	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood, 2016, 127, 3215-3224.	1.4	242
42	bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene, 1996, 13, 665-75.	5.9	235
43	Interleukin 15â€“mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nature Immunology, 2007, 8, 856-863.	14.5	231
44	The Proapoptotic BH3-Only Protein Bim Is Expressed in Hematopoietic, Epithelial, Neuronal, and Germ Cells. American Journal of Pathology, 2000, 157, 449-461.	3.8	214
45	The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO Journal, 1998, 17, 1029-1039.	7.8	210
46	The Bcl-2-regulated apoptotic pathway. Journal of Cell Science, 2003, 116, 4053-4056.	2.0	206
47	Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death and Differentiation, 2008, 15, 1564-1571.	11.2	205
48	Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death and Differentiation, 2007, 14, 128-136.	11.2	202
49	The BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell-Cycle Arrest. Cell, 2007, 129, 423-433.	28.9	189
50	BH3-only proteins and their roles in programmed cell death. Oncogene, 2008, 27, S128-S136.	5.9	189
51	Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands. Journal of Biological Chemistry, 2005, 280, 4738-4744.	3.4	187
52	Sensitization of BCL-2â€“expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2766-2771.	7.1	173
53	Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death and Differentiation, 2002, 9, 832-841.	11.2	170
54	Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood, 2012, 119, 5807-5816.	1.4	168

#	Article	IF	Citations
55	Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8512-8517.	7.1	166
56	The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1Î² Activation. Cell Reports, 2018, 25, 2339-2353.e4.	6.4	164
57	Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18081-18087.	7.1	162
58	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. Journal of Experimental Medicine, 2011, 208, 2017-2031.	8.5	162
59	Debcl, a Proapoptotic Bcl-2 Homologue, Is a Component of the Drosophila melanogaster Cell Death Machinery. Journal of Cell Biology, 2000, 148, 703-714.	5.2	161
60	(Î±/Î²+Î±)-Peptide Antagonists of BH3 Domain/Bcl-xL Recognition:â€‰ Toward General Strategies for Foldamer-Based Inhibition of Proteinâ^'Protein Interactions. Journal of the American Chemical Society, 2007, 129, 139-154.	13.7	160
61	A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. Journal of Cell Biology, 2008, 180, 341-355.	5.2	157
62	Î²TrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis. Molecular Cell, 2009, 33, 109-116.	9.7	157
63	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes and Development, 2014, 28, 58-70.	5.9	156
64	The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO Journal, 2003, 22, 1497-1507.	7.8	151
65	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood, 2017, 129, 3362-3370.	1.4	150
66	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood, 2016, 128, 1382-1395.	1.4	148
67	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science Translational Medicine, 2017, 9, .	12.4	148
68	Dynamic molecular monitoring reveals that SWIâ€“SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine, 2019, 25, 119-129.	30.7	147
69	Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9683-9688.	7.1	142
70	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications, 2019, 10, 2385.	12.8	139
71	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17961-17966.	7.1	137
72	The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO Journal, 1996, 15, 6979-90.	7.8	136

#	Article	IF	Citations
73	Gene structure, alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mammalian Genome, 2001, 12, 163-168.	2.2	133
74	Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16182-16187.	7.1	133
75	Pro-Apoptotic Apoptosis Proteaseâ€“Activating Factor 1 (Apaf-1) Has a Cytoplasmic Localization Distinct from Bcl-2 or Bcl-XL. Journal of Cell Biology, 2000, 149, 623-634.	5.2	132
76	Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochemical Pharmacology, 2002, 64, 851-863.	4.4	130
77	Targeting BCL2 for the Treatment of Lymphoid Malignancies. Seminars in Hematology, 2014, 51, 219-227.	3.4	130
78	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood, 2016, 128, 1834-1844.	1.4	127
79	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia, 2019, 33, 905-917.	7.2	126
80	A Structural Viral Mimic of Prosurvival Bcl-2:ÂAÂPivotal Role for Sequestering ProapoptoticÂBax and Bak. Molecular Cell, 2007, 25, 933-942.	9.7	125
81	Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity. ACS Chemical Biology, 2013, 8, 297-302.	3.4	123
82	HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. Cell Death and Disease, 2016, 7, e2051-e2051.	6.3	123
83	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia, 2018, 32, 303-312.	7.2	123
84	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood, 2020, 135, 773-777.	1.4	115
85	The Role of Bim, a Proapoptotic BH3â€Only Member of the Bclâ€2 Family, in Cellâ€Death Control. Annals of the New York Academy of Sciences, 2000, 917, 541-548.	3.8	113
86	A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nature Communications, 2015, 6, 6442.	12.8	112
87	VDAC2 enables BAX to mediate apoptosis and limit tumor development. Nature Communications, 2018, 9, 4976.	12.8	110
88	Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. Journal of Cell Biology, 2007, 177, 277-287.	5.2	109
89	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. Clinical Pharmacology and Therapeutics, 2017, 101, 89-98.	4.7	107
90	Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. Journal of Cell Biology, 2003, 162, 877-888.	5.2	104

#	Article	IF	Citations
91	Glucose Induces Pancreatic Islet Cell Apoptosis That Requires the BH3-Only Proteins Bim and Puma and Multi-BH Domain Protein Bax. Diabetes, 2010, 59, 644-652.	0.6	103
92	Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death and Differentiation, 2017, 24, 878-888.	11.2	103
93	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. PLoS Pathogens, 2010, 6, e1001236.	4.7	99
94	Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 2012, 18, 783-795.	7.0	98
95	BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10967-10971.	7.1	97
96	Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death and Differentiation, 2001, 8, 486-494.	11.2	94
97	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia, 2009, 23, 2034-2041.	7.2	91
98	Mesenchymal stromal cell apoptosis is required for their therapeutic function. Nature Communications, 2021, 12, 6495.	12.8	91
99	The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, F151-F178.	7.4	85
100	Proapoptotic BH3-Only Protein Bid Is Essential For Death Receptorâ€“Induced Apoptosis of Pancreatic Î²-Cells. Diabetes, 2008, 57, 1284-1292.	0.6	85
101	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. Genome Biology, 2021, 22, 310.	8.8	83
102	Bax activation by Bim?. Cell Death and Differentiation, 2009, 16, 1187-1191.	11.2	79
103	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia, 2014, 28, 1207-1215.	7.2	79
104	BCL2 and MCL1 inhibitors for hematologic malignancies. Blood, 2021, 138, 1120-1136.	1.4	78
105	MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation. Journal of Immunology, 2009, 183, 261-269.	0.8	76
106	Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis. Nature Microbiology, 2016, 1, 15034.	13.3	75
107	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 2021, 137, 2721-2735.	1.4	75
108	Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function.. Molecular and Cellular Biology, 1993, 13, 2420-2431.	2.3	73

#	Article	IF	Citations
109	Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood, 2012, 119, 4283-4290.	1.4	70
110	NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. Nature Communications, 2017, 8, 928.	12.8	69
111	Apoptosis and cell division. Current Opinion in Cell Biology, 2000, 12, 257-263.	5.4	66
112	Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. Biochemical Journal, 2004, 377, 597-605.	3.7	65
113	DR5 and caspase-8 are dispensable in ER stress-induced apoptosis. Cell Death and Differentiation, 2017, 24, 944-950.	11.2	65
114	IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood, 2018, 132, 2166-2178.	1.4	65
115	Quinazoline Sulfonamides as Dual Binders of the Proteins B-Cell Lymphoma 2 and B-Cell Lymphoma Extra Long with Potent Proapoptotic Cell-Based Activity. Journal of Medicinal Chemistry, 2011, 54, 1914-1926.	6.4	62
116	PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Medicine, 2021, 13, 58.	8.2	62
117	Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD. Journal of Immunology, 2000, 165, 1337-1343.	0.8	61
118	The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death and Disease, 2012, 3, e443-e443.	6.3	61
119	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X_L. Journal of Medicinal Chemistry, 2013, 56, 5514-5540.	6.4	60
120	Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Advances, 2019, 3, 4202-4214.	5.2	60
121	Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death and Differentiation, 2006, 13, 109-118.	11.2	58
122	Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle, 2008, 7, 39-44.	2.6	58
123	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229.	7.0	58
124	Transgenic overexpression of human Bcl-2 in islet Î² cells inhibits apoptosis but does not prevent autoimmune destruction. International Immunology, 2000, 12, 9-17.	4.0	56
125	FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. Blood, 2005, 106, 1581-1589.	1.4	56
126	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 4527-4533.	7.0	56

#	Article	IF	Citations
127	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	1.4	53
128	MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Cell Death and Disease, 2016, 7, e2345-e2345.	6.3	53
129	Cyclicâ€AMPâ€dependent protein kinase A regulates apoptosis by stabilizing the BH3â€only protein Bim. EMBO Reports, 2011, 12, 77-83.	4.5	52
130	Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies. Nature Communications, 2016, 7, 11734.	12.8	50
131	Synthesis of Biotinylated Episilvestrol: Highly Selective Targeting of the Translation Factors eIF4AI/II. Organic Letters, 2013, 15, 1406-1409.	4.6	49
132	Modifications and intracellular trafficking of FADD/MORT1 and caspase-8 after stimulation of T lymphocytes. Cell Death and Differentiation, 2004, 11, 724-736.	11.2	48
133	Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death and Differentiation, 1999, 6, 525-532.	11.2	45
134	Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death and Differentiation, 2003, 10, 185-192.	11.2	45
135	Plasma Membrane-Targeted ras GTPase-Activating Protein Is a Potent Suppressor of p21^{ras} Function. Molecular and Cellular Biology, 1993, 13, 2420-2431.	2.3	45
136	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2599-2604.	7.1	43
137	Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 261-266.	7.1	43
138	Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4044-4049.	7.1	43
139	Bclâ€2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupusâ€Prone Mice and Dampen Interferonâ€Î± Production. Arthritis and Rheumatology, 2015, 67, 797-808.	5.6	43
140	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death and Disease, 2012, 3, e409-e409.	6.3	42
141	ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. Journal of Clinical Oncology, 2014, 32, 7015-7015.	1.6	42
142	Direct addition of BimL to mitochondria does not lead to cytochromecrelease. FEBS Letters, 2002, 522, 29-34.	2.8	41
143	Sheeppox Virus SPPV14 Encodes a Bcl-2-Like Cell Death Inhibitor That Counters a Distinct Set of Mammalian Proapoptotic Proteins. Journal of Virology, 2012, 86, 11501-11511.	3.4	41
144	Deerpox Virus Encodes an Inhibitor of Apoptosis That Regulates Bak and Bax. Journal of Virology, 2011, 85, 1922-1934.	3.4	40

#	Article	IF	Citations
145	Rapid Hybridoma Screening Method for the Identification of Monoclonal Antibodies to Low-Abundance Cytoplasmic Proteins. BioTechniques, 1998, 25, 824-830.	1.8	39
146	KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. Journal of Controlled Release, 2019, 296, 40-53.	9.9	39
147	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances, 2021, 5, 4054-4058.	5.2	39
148	Replication stress induces mitotic death through parallel pathways regulated by WAPL and telomere deprotection. Nature Communications, 2019, 10, 4224.	12.8	38
149	Structure-Guided Rescaffolding of Selective Antagonists of BCL-X_L. ACS Medicinal Chemistry Letters, 2014, 5, 662-667.	2.8	37
150	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. British Journal of Haematology, 2019, 186, e188-e191.	2.5	37
151	Bcl-2 does not inhibit cell death induced by the physiological Fas ligand: implications for the existence of typeâ€‰I and typeâ€‰II cells. Cell Death and Differentiation, 2000, 7, 754-755.	11.2	36
152	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology, 2011, 43, 525-535.	0.6	36
153	Virally mediated inhibition of Bax in leukocytes promotes dissemination of murine cytomegalovirus. Cell Death and Differentiation, 2009, 16, 312-320.	11.2	35
154	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. Cell Reports, 2016, 14, 1858-1866.	6.4	35
155	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. Cell Death and Differentiation, 2020, 27, 1554-1568.	11.2	35
156	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207.	1.4	34
157	Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death and Differentiation, 2010, 17, 821-832.	11.2	33
158	De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-X_L: Synthesis, Structural and Biochemical Characterization. Journal of Medicinal Chemistry, 2014, 57, 1323-1343.	6.4	33
159	MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. Cell Death and Differentiation, 2020, 27, 2484-2499.	11.2	33
160	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. Blood, 2019, 134, 170-170.	1.4	33
161	Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes. Diabetologia, 2015, 58, 140-148.	6.3	32
162	Pro-apoptotic BH3-only Bcl-2 family members in vertebrate model organisms suitable for genetic experimentation. Cell Death and Differentiation, 2002, 9, 1163-1166.	11.2	31

#	Article	IF	Citations
163	A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis. Nature Chemical Biology, 2019, 15, 1057-1066.	8.0	30
164	Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 Proteins. Journal of Biological Chemistry, 2009, 284, 31315-31326.	3.4	29
165	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Leukemia, 2016, 30, 1531-1541.	7.2	29
166	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death and Differentiation, 2020, 27, 2217-2233.	11.2	29
167	Control of Apoptosis in Hematopoietic Cells by the Bcl-2 Family of Proteins. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64, 351-358.	1.1	29
168	The Role of the Proâ€Apoptotic Bclâ€2 Family Member Bim in Physiological Cell Death. Annals of the New York Academy of Sciences, 2000, 926, 83-89.	3.8	28
169	Infection with flaviviruses requires BCLXL for cell survival. PLoS Pathogens, 2018, 14, e1007299.	4.7	28
170	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Advances, 2020, 4, 2762-2767.	5.2	28
171	Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood, 2022, 140, 2127-2141.	1.4	28
172	Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death and Disease, 2010, 1, e43-e43.	6.3	26
173	Variability of Inducible Expression across the Hematopoietic System of Tetracycline Transactivator Transgenic Mice. PLoS ONE, 2013, 8, e54009.	2.5	26
174	Further Insights into the Effects of Pre-organizing the BimBH3 Helix. ACS Chemical Biology, 2014, 9, 838-839.	3.4	26
175	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 469-477.	1.1	26
176	The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics. Journal of Immunology, 2010, 185, 2555-2562.	0.8	25
177	TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer. Cell Death and Differentiation, 2021, 28, 3316-3328.	11.2	25
178	Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition. MedChemComm, 2014, 5, 1834-1842.	3.4	24
179	Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Cell Death and Differentiation, 2016, 23, 2054-2062.	11.2	24
180	CED-4 forms a 2â€‰:â€‰2 heterotetrameric complex with CED-9 until specifically displaced by EGL-1 or CED-13. Cell Death and Differentiation, 2006, 13, 426-434.	11.2	23

#	Article	IF	Citations
181	Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 1298-1303.	2.8	23
182	Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the Pathway. ACS Chemical Biology, 2020, 15, 2702-2713.	3.4	22
183	BH3-only proteins: orchestrating cell death. Cell Death and Differentiation, 2006, 13, 1268-1271.	11.2	21
184	MCMV-mediated Inhibition of the Pro-apoptotic Bak Protein Is Required for Optimal In Vivo Replication. PLoS Pathogens, 2013, 9, e1003192.	4.7	21
185	Current challenges and novel treatment strategies in double hit lymphomas. Therapeutic Advances in Hematology, 2016, 7, 52-64.	2.5	20
186	CARM1-mediated methylation of protein arginine methyltransferase 5 represses human Î³-globin gene expression in erythroleukemia cells. Journal of Biological Chemistry, 2018, 293, 17454-17463.	3.4	20
187	Total Synthesis of 2â€²,5â€²-Diepisilvestrol and Its C1â€´ Epimer: Key Structure Activity Relationships at C1â€´ and C2â€´. Journal of Natural Products, 2012, 75, 1500-1504.	3.0	19
188	The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia, 2021, 35, 2114-2118.	7.2	18
189	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. Cancer Discovery, 2022, 12, 774-791.	9.4	18
190	Simplified Silvestrol Analogues with Potent Cytotoxic Activity. ChemMedChem, 2014, 9, 1556-1566.	3.2	16
191	Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy. MedChemComm, 2016, 7, 778-787.	3.4	16
192	BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock toÂReprogramming. Stem Cell Reports, 2018, 10, 331-338.	4.8	16
193	The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. Oncotarget, 2016, 7, 2721-2733.	1.8	16
194	Response: Does Bid Play a Role in the DNA Damage Response?. Cell, 2007, 130, 10-11.	28.9	14
195	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, 2021, 12, 5337.	12.8	14
196	Induction of antigenâ€specific effectorâ€phase tolerance following vaccination against a previously ignored Bâ€cell lymphoma. Immunology and Cell Biology, 2011, 89, 595-603.	2.3	13
197	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Blood, 2020, 136, 7-8.	1.4	13
198	Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. British Journal of Haematology, 1992, 81, 231-234.	2.5	12

#	Article	IF	Citations
199	Rapid Selection against Truncation Mutants in Yeast Reverse Two-Hybrid Screens. BioTechniques, 2001, 30, 984-988.	1.8	12
200	Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis. Journal of Leukocyte Biology, 2011, 90, 819-829.	3.3	12
201	BH3 Mimetics for the Treatment of B-Cell Malignanciesâ€"Insights and Lessons from the Clinic. Cancers, 2020, 12, 3353.	3.7	12
202	Transgenic, inducible RNAi in megakaryocytes and platelets in mice. Journal of Thrombosis and Haemostasis, 2010, 8, 2751-2756.	3.8	11
203	Synthesis and biological evaluation of a potent salicylihalamide A lactam analogue. Organic and Biomolecular Chemistry, 2012, 10, 8147.	2.8	11
204	Protein hijacking. Cancer Cell, 2004, 5, 107-108.	16.8	10
205	EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency. Cell Death and Differentiation, 2008, 15, 1609-1618.	11.2	10
206	Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins. Oncogene, 2017, 36, 4953-4962.	5.9	10
207	Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. Cell Death and Differentiation, 2019, 26, 1516-1530.	11.2	10
208	Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell Death and Disease, 2020, 11, 735.	6.3	10
209	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. Blood, 2013, 122, 1304-1304.	1.4	10
210	The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL. Cell Death and Disease, 2022, 13, 291.	6.3	10
211	A Biosensor of Src Family Kinase Conformation by Exposable Tetracysteine Useful for Cell-Based Screening. ACS Chemical Biology, 2014, 9, 1426-1431.	3.4	9
212	A Chemical Screening Approach to Identify Novel Key Mediators of Erythroid Enucleation. PLoS ONE, 2015, 10, e0142655.	2.5	8
213	Transcriptional silencing of fetal hemoglobin expression by NonO. Nucleic Acids Research, 2021, 49, 9711-9723.	14.5	7
214	Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells. Cell Death and Differentiation, 2020, 27, 2531-2533.	11.2	6
215	Nuclear localisation of FADD â€“ rebuttal. Cell Death and Differentiation, 2004, 11, 1362-1363.	11.2	5
216	Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X_L and BCL-2. Journal of Medicinal Chemistry, 2021, 64, 5447-5469.	6.4	5

#	Article	IF	Citations
217	Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax. Blood, 2019, 134, 171-171.	1.4	5
218	BH3-mimetics â€“ the solution to chemoresistance?. Leukemia and Lymphoma, 2009, 50, 1069-1072.	1.3	4
219	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	1.4	4
220	Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia. Oncotarget, 2017, 8, 57948-57963.	1.8	4
221	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 909-911.	1.3	2
222	Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting. Blood, 2014, 124, 988-988.	1.4	2
223	Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax. Blood, 2016, 128, 3223-3223.	1.4	2
224	Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM. Blood, 2019, 134, 3103-3103.	1.4	2
225	BCL2 inhibition in double hit lymphoma. Leukemia and Lymphoma, 2015, 56, 1928-1929.	1.3	1
226	A transgenic mouse model to inducibly target prosurvival Bcl2 proteins with selective BH3 peptides in vivo. Cell Death and Disease, 2015, 6, e1679-e1679.	6.3	1
227	Venetoclax for the treatment of mantle cell lymphoma. Annals of Lymphoma, 2019, 3, 4-4.	4.5	1
228	Correction for Fletcher et al., Inaugural Article: Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1678-1678.	7.1	0
229	197. Cytokine, 2014, 70, 75-76.	3.2	0
230	Megakaryocytes Possess a Functional Intrinsic Apoptosis Pathway That Must Be Restrained In Order to Survive and Produce Platelets. Blood, 2010, 116, 550-550.	1.4	0
231	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. Journal of Cell Biology, 2011, 194, i12-i12.	5.2	0
232	Abstract A19: The selective targeting of cell survival pathways in leukemia. , 2013, , .		0
233	Targeting the Pro-Survival BCL2 Proteins with BH3 Mimetic Compounds for Treating Multiple Myeloma. Blood, 2016, 128, 3293-3293.	1.4	0
234	The Role of BAX/BAK-Mediated Apoptosis for the Cytotoxic Action of Anti-Myeloma Agents. Blood, 2016, 128, 5706-5706.	1.4	0